RPG LIFESCI

RPG Life Sciences Ltd. is engaged in the development, manufacture, and market of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2008-06-10. The firm operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas, including nephrology, oncology, rheumatology, cardiology, respiratory, nutritional, gastroenterology, and diabetology, among others. The international formulations business is involved in developing, manufacturing and marketing oral solid formulations in the generic and branded generic space across regulated and emerging markets. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Sodium Valproate PR, Nicorandil, Quinfamide, Nicorandil, Haloperidol, Risperidone, and others.